Oscar Health, Inc. reported strong financial results for the first quarter of 2025, surpassing analyst expectations. The company posted revenue of $3.05 billion, a 42% increase year-over-year, exceeding the estimated $2.87 billion. Net income rose 55% year-over-year to $275.3 million, while diluted earnings per share (EPS) reached $0.92, beating the estimated $0.81. Adjusted EBITDA increased 50% year-over-year to $328.8 million. The medical loss ratio (MLR) was 75.4%, slightly higher than the previous year's 74.2%, and the selling, general and administrative (SG&A) expense ratio stood at 15.8%. Oscar Health's membership base surpassed 2 million. CEO Mark Bertolini highlighted the company's continued top-line growth and bottom-line performance. The company reaffirmed its 2025 revenue guidance of $11.2 billion to $11.3 billion and operating earnings guidance of $225 million to $275 million. Following the earnings release, Oscar Health's stock rose by over 15%, with investors expressing confidence in the company's long-term growth prospects and some anticipating the stock reaching $35 to $45 in the coming years.